Skip to Main Content

Paper Details

Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
J Neurooncol
2
2023
CCNU, CeTeG, HAE, MGMT, NOA, TMZ, glioblastoma, hematotoxicity, hematotoxicity adverse, lomustine, patients, temozolomide
Author NameAffiliation
Theophilos TzaridisDivision of Clinical Neurooncology, University Hospital Bonn
Ghazaleh TabatabaiUniversity Hospital Tubingen, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center Tubingen-Stuttgart, Eberhard Karls University
Peter VajkoczyCharite University of Berlin
Martin GlasDivision of Clinical Neurooncology, Department of Neurology and West German Cancer Center (WTZ), University Hospital Essen
Hartmut VatterUniversity Hospital Bonn
  • 1 - 5

Datasets

Release 1.2